A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AB-452 Following Oral Administration in Healthy Subjects and Subjects with Chronic Hepatitis B
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 16 Jul 2019
Price : $35 *
At a glance
- Drugs AB-452 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; First in man
- Sponsors Arbutus Biopharma
- 12 Nov 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 09 Oct 2018 According to an Arbutus Biopharma media release, the company expects Phase I initiation to be delayed as the company is working on completing ongoing non-clinical studies.
- 28 Aug 2018 Status changed from planning to not yet recruiting.